Skip to main content
Equibles

J. Goldman & Co LP

Position in KPTI — Karyopharm Therapeutics Inc.

CIK 1412741 NEW YORK, NY
Back to KPTI Full portfolio

Position in KPTI

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$659,475
+$498,675 QoQ
Shares Held
67,500
+743.8% QoQ
Ownership
0.298%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#41
of 96 holders
Holding Since
Mar 2020
11 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in KPTI Over Time

Shares Held

Position Value (USD)

Derivatives in KPTI

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$660,452
PutShares
67,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

J. Goldman & Co LP holds $154,729,761 across 52 Biotechnology names. KPTI ranks #41 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 COGT
Cogent Biosciences, Inc.
 637,994 $24,690,367
2 ALNY
Alnylam Pharmaceuticals, Inc.
 38,698 $11,649,258
3 CAPR
Capricor Therapeutics, Inc.
 427,321 $10,289,889
4 MGTX
MeiraGTx Holdings plc
 601,972 $8,132,641
5 ARDX
Ardelyx, Inc.
 1,579,828 $8,057,122
6 URGN
UroGen Pharma Ltd.
 212,775 $7,830,120
7 VRTX
Vertex Pharmaceuticals Inc / Ma
 12,311 $6,115,243
8 ELVN
Enliven Therapeutics, Inc.
 112,129 $5,690,546

All Filings in KPTI

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $659,475 67,500
2026-06-30 $660,452 67,600
2023-09-30 $160,800 120,000
2023-06-30 $966,138 539,742
2021-12-31 $1,763,382 274,243
2021-09-30 $335,965 57,726
2021-06-30 $10,371,207 1,004,962
2021-03-31 $14,003,214 1,331,104
2020-12-31 $4,051,564 261,729
2020-09-30 $820,520 56,200
2020-09-30 $2,655,798 181,904
2020-06-30 $1,917,656 101,249
2020-03-31 $543,450 28,290